Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses

MT Newswires Live12-09

Cullinan Therapeutics (CGEM) said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed "promising" efficacy, including multiple complete responses.

For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.

Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.

Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.

Development of CLN-049 will proceed under the US Food and Drug Administration's Fast Track designation, the company said.

Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.

Shares of the company were up 12% in recent Monday trading.

Price: 11.66, Change: +1.07, Percent Change: +10.10

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590357546?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 00:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590357546","market":"fut","top_or_hot":-1,"title":"Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed \"promising\" efficacy, including multiple complete responses.</p><p>For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.</p><p>Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.</p><p>Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.</p><p>Development of CLN-049 will proceed under the US Food and Drug Administration's <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation, the company said.</p><p>Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.</p><p>Shares of the company were up 12% in recent Monday trading.</p><p>Price: 11.66, Change: +1.07, Percent Change: +10.10</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCullinan Therapeutics Says Data From Early-Stage Acute Myeloid Leukemia Trial Showed Multiple Complete Responses\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-09 00:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/CGEM\">Cullinan Therapeutics</a> (CGEM) said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed \"promising\" efficacy, including multiple complete responses.</p><p>For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.</p><p>Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.</p><p>Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.</p><p>Development of CLN-049 will proceed under the US Food and Drug Administration's <a href=\"https://laohu8.com/S/FTRK\">Fast Track</a> designation, the company said.</p><p>Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.</p><p>Shares of the company were up 12% in recent Monday trading.</p><p>Price: 11.66, Change: +1.07, Percent Change: +10.10</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CGEM","symbol_name":"Cullinan Therapeutics","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2590357546","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2590357546","pubTimestamp":1765213191,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Cullinan Therapeutics  said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed \"promising\" efficacy, including multiple complete responses.For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.Development of CLN-049 will proceed under the US Food and Drug Administration's Fast Track designation, the company said.Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.Shares of the company were up 12% in recent Monday trading.Price: 11.66, Change: +1.07, Percent C","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CGEM":"Cullinan Therapeutics","BK4139":"生物科技","SSI":"Stage Stores Inc"},"translate_title":"Cullinan Therapeutics表示早期急性髓系白血病试验数据显示多项完全缓解","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CGEM":1.5,"SSI":1.5},"content_text":"Cullinan Therapeutics (CGEM) said Monday that data from its early-stage trial evaluating the CLN-049 monotherapy candidate in acute myeloid leukemia and myelodysplastic syndrome showed \"promising\" efficacy, including multiple complete responses.For acute myeloid leukemia, the company said the complete response to complete remission with partial hematologic recovery rate was 31%, at the highest target dose tested to date.Efficacy endpoints of the study include complete response rate and composite complete response rate, the company said.Initial dose escalation results in 45 patients demonstrated a favorable safety profile across all doses assessed, the company said.Development of CLN-049 will proceed under the US Food and Drug Administration's Fast Track designation, the company said.Dose escalation is continuing in this ongoing phase 1 study, with expansion groups planned in early 2026, it added.Shares of the company were up 12% in recent Monday trading.Price: 11.66, Change: +1.07, Percent Change: +10.10","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590357546","isCrawlerRequest":true}